| [1] |
Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations [J]. J Clin Oncol,2003,21(13):2600-2608.
|
| [2] |
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 [J]. J Clin Oncol,1997,15(7):2483-2493.
|
| [3] |
Kuerer HM, Newman LA, Buzdar AU, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status[J]. Cancer J Sci Am,1998,4:230-236.
|
| [4] |
Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J]. J Clin Oncol,1998,16(8):2672-2685.
|
| [5] |
Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [J]. J Clin Oncol, 2007,25(33):5287-5312.
|
| [6] |
Bonnefoi H, Underhill C, Iggo R, et al. Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic? [J]. Eur J Cancer, 2009,45(10):1733-1743.
|
| [7] |
Roukos HD. Twenty-One-Gene Assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer [J]. J Clin Oncol, 2009,27(8):1337-1338.
|
| [8] |
Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer [J]. N Engl J Med,2009, 360(8):790-800.
|
| [9] |
van TVL, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer [J]. Nature,2002,415(6871):530-536.
|
| [10] |
de Vijver VJM, He YD, van T Veer LJ, et al. A Gene-expression signature as a predictor of survival in breast cancer [J]. N Engl J Med,2002,347(25):1999-2009.
|
| [11] |
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours [J]. Nature,2000,406(6797):747-752.
|
| [12] |
Therese S, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. PNAS,2001,98(19):10869-10874.
|
| [13] |
Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients [J].Breast Cancer Res,2006,8(4):R34.
|
| [14] |
Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res,2005,11(16):5678-5685.
|
| [15] |
Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer [J]. Lancet,2003,362(9381):362-369.
|
| [16] |
Luca G, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer [J]. J Clin Oncol, 2005,23(29):7265-7277.
|
| [17] |
Iwao Koizumi K, Matoba R, Ueno N, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling[J]. J Clin Oncol,2005,23(3):422-431.
|
| [18] |
Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J]. J Clin Oncol,2004,22(12):2284-2293.
|
| [19] |
Bonnefoi H, Potti A, Delorenzi M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial [J]. Lancet Oncol,2007,8(12):1071-1078.
|
| [20] |
Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics [J]. Nat Med,2006,12(11):1294-1300.
|
| [21] |
Chang JC, Wooten EC, Tsimelzon A, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients [J]. J Clin Oncol,2005,23(6):1169-1177.
|
| [22] |
Dressman HK, Hans C, Bild A, et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy [J]. Clin Cancer Res,2006,12(3 Pt1):819-826.
|
| [23] |
Folgueira K, Azevedo MA, Carraro DM, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer [J]. Clin Cancer Res,2005,11(20):7434-7443.
|
| [24] |
Olaf T, Schneeweiss A, Toedt G, et al. Gene expression signature predicting pathologic complete response with gemcitabine,epirubicin, and docetaxel in primary breast cancer [J]. J Clin Oncol,2006, 24(12):1839-1845.
|
| [25] |
Park S, Shimizu C, Shimoyama T, et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat [J],2006,99(1):9-17.
|
| [26] |
Cleator S, Tsimelzon A, Ashworth A, et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide(Cytoxan)(AC) response and resistance [J]. Breast Cancer Res Tr,2006(3), 95:229-233.
|
| [27] |
Hess RK, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer [J]. J Clin Oncol,2006,24(26):4236-4244.
|
| [28] |
Mina L, Soule SE, Badve S, et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue [J]. Breast Cancer Res Treat,2007,103(2):197-208.
|
| [29] |
Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [J]. Clin Cancer Res,2004,10(16):5367-5374.
|
| [30] |
Carey AL, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res,2007,13(8):2329-2334.
|
| [31] |
Dent R, Trudeau M, Pritchard KI,et al. Triple-negative breast cancer: clinical features and patterns of recurrence [J]. Clinc Cancer Res,2007,13(15 Pt):4429-4434.
|
| [32] |
Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer [J]. Ann Oncol,2008,19(11):1847-1852.
|
| [33] |
Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J]. J Clin Oncol,2008,26(8):1275-1281.
|
| [34] |
Chuthapisith S, Layfield R, Kerr ID, et al. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs [J]. Int J Oncol,2007,30(6):1545-1551.
|
| [35] |
Smith L, Welham KJ, Watson MB, et al. The proteomic analysis of cisplatin resistance in breast cancer cells [J]. Oncol Res,2007,16(11):497-506.
|
| [36] |
Brozkova K, Budinska E, Bouchal P, et al. Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression [J]. Breast Cancer Res,2008,10(3):R48.
|
| [37] |
Raihanatou D, Ting E, Gluz O, et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy[J]. Clin Cancer Res,2007, 13:488-497.
|
| [38] |
Smith L, Watson MB, O'Kane SL, et al. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays [J]. Mol Cancer Ther,2006,5(8):2115-2120.
|
| [39] |
Goncalves A, Bertucci F, Birnbaum D, et al. Proteic profiling SELDI-TOF and breast cancer: clinical potential applications[J]. Med Sci (Paris), 2007,23(spec No1),1:23-26.
|
| [40] |
Cheng F, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer [J]. N Engl J Med,2006,355(6):560-569.
|